Maze Therapeutics Corp (MAZE) - Enterprise Value to EBITDA Ratio

mazetx.com (MAZE) - corporate logo

Maze Therapeutics Inc (MAZE) utilizes AI-driven DNA mapping to develop unique, patent-protected drugs. The shift in the EV/EBITDA ratio confirms the market valuation, where the metric remains around 0.00. The reliability of these developments is ensured by the air transport of ultra-sensitive reagents in deep-freeze conditions. Additionally, the company relies on a network of specialized operators to ensure the uninterrupted supply of biomaterials to its laboratories.

Maze Therapeutics, Inc. - MAZE Business Value to Operating Income Before Depreciation (period 11/23/2025 - 11/15/2026)

Comprehensive metric breakdowns and analytics for Maze Therapeutics (MAZE)

- stock price and consensus target price:
Fundamental company analysis:MAZE (Maze Tx)
Original product of mazetx.com

The EV/EBITDA multiple determines the total enterprise value of a business relative to its operating profit before depreciation and interest, allowing an investor to assess the real price of an asset while accounting for debt load. By analyzing the historical EV/EBITDA chart for Maze Therapeutics Inc. (MAZE), one can track market expectations regarding the commercialization of innovative therapies for rare genetic diseases in the absence of current revenue.

Direct competitors

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempus AI TEM|qiagen.com (QGEN) - Company Value to EBITDA|IONS: Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Multiple Repligen (RGEN)|RNA (Avidity) - Enterprise Value to EBITDA Ratio|CRISPR Therapeutics AG - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GeneDx Holdings|Enterprise Value to Operating Income Before Depreciation RARE (Ultragenyx)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Beam Therapeutics (BEAM)|Enterprise Value to Operating Income Before Depreciation Ratio SRPT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Twist Bioscience Corp TWST|Total Company Value to Operating Income Before Depreciation Ratio 10x Genomics, Inc. (TXG)|Intellia Therapeutics - EV/EBITDA Multiple|STOK - EV/EBITDA Multiple|BLFS (biolifesolutions.com) - Enterprise Value to EBITDA Ratio|WVE - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sionna Therapeutics|Enterprise Value to Operating Income Before Depreciation PRME (Prime Medicine Corp)|EV/EBITDA Multiple TSHA|EV/EBITDA Multiple uniqure.com (QURE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MeiraGTx PLC MGTX|Business Value to Operating Income Before Depreciation RGNX|solidbio.com - EV/EBITDA Multiple|OCGN (Ocugen Pharma) - Enterprise Value to Operating Income Before Depreciation|PACB: EV/EBITDA Multiple|Benitec Biopharma (BNTC) - EV/EBITDA Multiple|DSGN (Design Therapeutics Inc) - EV/EBITDA Multiple|Rocket Pharmaceuticals, Inc. (RCKT) - Total Company Value to Operating Income Before Depreciation Ratio|FDMT - Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LXEO (Lexeo)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization korrobio.com KRRO|Total Company Value to Operating Income Before Depreciation Ratio Editas Medicine, Inc. (EDIT)|SLN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio ProQR PRQR|CDXS: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Sangamo BioSciences SGMO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nautilus Bio|MGX (Metagenomi, Inc.) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple DTIL|Generation Bio - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple BOLD (Boundless Bio Inc.)|Business Value to Operating Income Before Depreciation XCUR|Imunon Inc - EV/EBITDA Multiple|PHIO (phiopharma.com) - Enterprise Value to Operating Income Before Depreciation|MBIO (mustangbio.com) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation RNAZ|BNGO (Bionano) - EV/EBITDA Multiple|EV/EBITDA Multiple Applied DNA Corp|EV/EBITDA Multiple BLUE|EV/EBITDA Multiple ImmunoPrecise Antibodies Ltd. (IPA)|EV/EBITDA Multiple OMGA (omegatherapeutics.com)|OMIC: Enterprise Value to Operating Income Before Depreciation|RGLS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SYRS (Syros Pharmaceuticals, Inc)|TBIO: EV/EBITDA Multiple|TRACON Pharmaceuticals (TCON) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology, Inc